RayKnowChina Research Map
Shortlist

Kunming Medical University

昆明医科大学

KunmingUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.7%Leads under 1 in 100 of China's research papers on NPC

Led 17 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025
ThemesRadiotherapy techniqueInduction / concurrent chemotherapyRecurrent / metastatic disease

Hospitals counted here

  1. Yunnan Cancer Hospital9
  2. First Affiliated Hospital of Kunming Medical University6
  3. Second Affiliated Hospital of Kunming Medical University Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Impact of smoking and alcohol drinking on the prognosis of 721 nasopharyngeal carcinoma.2025Brazilian journal of otorhinolaryngologyFree full text
  2. Effect of waiting time for radiotherapy after last induction chemotherapy on prognosis of locally advanced nasopharyngeal carcinoma.2024Head & neck
  3. Concurrent chemoradiotherapy versus radiotherapy alone for stage II nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.2023European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  4. The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study.2022Radiation oncology (London, England)Free full text
  5. Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma.2021Technology in cancer research & treatmentFree full text
Trials on ClinicalTrials.gov6
  1. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  2. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  3. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  4. Clincal Study of Reduced Target Radiotherapy in Nasopharyngeal CarcinomaCompletedNCT05741008Lead sponsorN/AStart 2023-01
  5. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  6. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.1%Leads under 1 in 100 of China's research papers on ESCC

Led 4 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 002025
ThemesImmunotherapySurgeryNeoadjuvant & combined treatment

Hospitals counted here

  1. First Affiliated Hospital of Kunming Medical University3
  2. Yunnan Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led4
  1. Is neoadjuvant chemotherapy combined with immunotherapy really better than neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma?2024The Journal of thoracic and cardiovascular surgery
  2. Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis.2024Chemico-biological interactions
  3. Circular RNA circ-SLC7A5 Functions as a Competing Endogenous RNA to Impact Cell Biological Behaviors in Esophageal Squamous Cell Carcinoma (ESCC).2024Cell biochemistry and biophysics
  4. The DMRTA1-SOX2 positive feedback loop promotes progression and chemotherapy resistance of esophageal squamous cell carcinoma.2023Oncology researchFree full text
Trials on ClinicalTrials.gov6
  1. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  2. Standardized MRI and Structured Reporting for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07769658Study siteStart 2026-09
  3. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08
  4. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  5. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  6. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.5%Leads under 1 in 100 of China's research papers on HCC

Led 71 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
71
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025
ThemesRecurrence & prognosisSurgery & liver transplantImaging, AI & early detection

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital of Kunming Medical University28
  2. First Affiliated Hospital of Kunming Medical University Counted in the group total13
  3. Yunnan Cancer Hospital Counted in the group total11
  4. Affiliated Hospital of Kunming Medical University9
  5. Affiliated Calmette Hospital of Kunming Medical University3
  6. Yan'An Hospital, Kunming Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Robotic vs Open Liver Resection for Hepatocellular Carcinoma.2023JAMA surgery
  2. Robotic vs Open Liver Resection for Hepatocellular Carcinoma.2023JAMA surgery
  3. Efficacy and safety of indocyanine green fluorescence navigation versus conventional laparoscopic hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.2025Surgical endoscopy
  4. A case report of laparoscopy combined with ultrasound-guided percutaneous radiofrequency ablation for liver tumors.2024Asian journal of surgery
  5. Needle-track seeding following percutaneous radiofrequency ablation of hepatocellular carcinoma in the caudate lobe: A case report.2024Asian journal of surgery
Trials on ClinicalTrials.gov6
  1. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07
  2. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  3. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  4. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  5. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  6. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Study sitePhase 1/Phase 2Start 2019-07

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.2%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 24 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
2
Research papers it led
24
Trials it led
3
Share of China's trials
0.2%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesPeritoneal spread & advanced diseaseImaging & AIEarly detection & endoscopy

Hospitals counted here

  1. Yunnan Cancer Hospital8
  2. First Affiliated Hospital of Kunming Medical University Counted in the group total6
  3. Second Affiliated Hospital of Kunming Medical University Counted in the group total4
  4. Kunming Medical University Second Hospital1
  5. Affiliated Cardiovascular Hospital of Kunming Medical University Counted in the group total1
  6. Yan'an Hospital, Kunming Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. CT feature of irregular extensive ulceration as a predictor of liver metastasis in gastric gastrointestinal stromal tumours.2025European radiology
  2. CT-based scores for extramural vascular invasion and occult peritoneal metastasis correlate with gastric cancer survival.2025European radiology
  3. Predictive value of enhanced CT and pathological indicators in lymph node metastasis in patients with gastric cancer based on GEE model.2025BMC medical imagingFree full text
  4. Creeping gastric cancer was found after gastrectomy: A case report.2024Asian journal of surgery
  5. Lymph node metastasis in small intestinal gastrointestinal stromal tumors: A rare case report and literature review.2024Asian journal of surgery
Trials on ClinicalTrials.gov6
  1. The Application Value of Spectral CT in the Accurate Staging of Gastric CancerNot yet recruitingNCT06977386Lead sponsorN/AStart 2025-06
  2. Study on the Value of Three DWI Scanning Sequences in Staging of Gastric CancerRecruitingNCT06735105Lead sponsorN/AStart 2023-12
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  4. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Study sitePhase 2/Phase 3Start 2024-02
  5. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Study sitePhase 2Start 2023-11
  6. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Study sitePhase 3Start 2023-04

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.5%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 11 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Yunnan Cancer Hospital3
  2. First Affiliated Hospital of Kunming Medical University2
  3. Sixth Affiliated Hospital of Kunming Medical University2
  4. Affiliated Hospital of Kunming Medical University1
  5. Affiliated Stomatology Hospital of Kunming Medical University1
  6. Yan'an Hospital, Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.3%Leads about 1 in 75 of China's research papers on Gastrointestinal stromal tumour ▲ from 0.3%

Led 7 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Hospitals counted here

  1. Yunnan Cancer Hospital3
  2. Second Affiliated Hospital of Kunming Medical University3
  3. Affiliated Hospital of Kunming Medical University1
  4. Tumor Hospital, Third Affiliated Hospital To Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.5%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 6 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Kunming Medical University3
  2. Second Affiliated Hospital of Kunming Medical University2
  3. Sixth Affiliated Hospital of Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma New since 2021

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.06%Leads under 1 in 100 of China's research papers on Myeloma New since 2021

Led 1 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.01%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025
ThemesDrug combinations

Hospitals counted here

  1. Yunnan Cancer Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.0%Leads none of China's research papers on B-ALL

Led 0 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
2
Share of China's trials
0.8%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.7%Leads under 1 in 100 of China's research papers on Haemophilia A New since 2021

Led 2 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Kunming Medical University1
  2. Second Affiliated Hospital of Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
3.1%Leads about 1 in 32 of China's research papers on Thrombotic thrombocytopenic purpura New since 2021

Led 2 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital of Kunming Medical University2
  2. Affiliated Cardiovascular Hospital of Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.2%Leads under 1 in 100 of China's research papers on NMOSD

Led 1 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025
ThemesAcute attack treatmentAntibodies & diagnosis

Hospitals counted here

  1. First Affiliated Hospital of Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
0.6%Leads under 1 in 100 of China's research papers on Moyamoya New since 2021

Led 2 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025
ThemesRevascularisation surgeryImaging & blood flowStroke & bleeding outcomes

Hospitals counted here

  1. First Affiliated Hospital of Kunming Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.1%Leads about 1 in 88 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 3 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Kunming Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.5%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 5 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital of Kunming Medical University2
  2. First Affiliated Hospital of Kunming Medical University1
  3. Affiliated Hospital of Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.1%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis ▼ from 0.8%

Led 1 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.02%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
4.3%Leads about 1 in 23 of China's research papers on Primary biliary cholangitis ▲ from 0.7%

Led 13 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Second Affiliated Hospital of Kunming Medical University12
  2. Neurology First Affiliated Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hereditary angioedema

遗传性血管性水肿
3.1%Leads about 1 in 32 of China's research papers on Hereditary angioedema New since 2021

Led 1 of 32 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Yan'an Hospital, Kunming Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Efficacy and safety of Donidalorsen in Hereditary Angioedema with C1 inhibitor deficiency: a systematic review and a meta analysis.2024Archives of dermatological research
Trials on ClinicalTrials.gov2
  1. A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruitingNCT06846398Study sitePhase 2Start 2025-02
  2. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
10.2%Leads about 1 in 10 of China's research papers on Familial adenomatous polyposis ▲ from 3.9%

Led 6 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 2220242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Kunming Medical University3
  2. Second Affiliated Hospital of Kunming Medical University2
  3. Yunnan Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov